Stockreport

Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy

FIBROCELL SCIENCE INC COMMON  (FCSC) 
NASDAQ:AMEX Investor Relations: fibrocell.com
PDF - Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and a 30% gross profit share - - Fibrocell retains [Read more]